U.S. Online Retail and Ecommerce Stock News

In June 2026, Mobileye Global announced plans to expand beyond supplying self-driving technology by launching a fully owned, vertically integrated autonomous ride-hailing business in a major U.S. city from 2027, starting with about 100 robotaxis and aiming to scale materially over the following five years. This move shifts Mobileye closer to an end‑to‑end mobility operator, combining its Mobileye Drive system with Moovit’s massive user base and global multimodal mobility platform into a...

Short-term traders and long-term holders alike may be asking the same question about International Business Machines right now: is the current share price giving you fair value for the risk you are taking? Over the past week the stock gained 3.7%, and it is up 3.0% over the last month, even though the year to date return is down 11.4% and the 1 year return is down 9.3%, compared to a much stronger 112.2% return over 3 years and 123.9% over 5 years. Recent headlines around International...

Brown & Brown (NYSE:BRO) has been recognized in 2026 for its workplace culture and mental health programs. The company was named to the Best Workplaces in Financial Services & Insurance and Best Workplaces for Mental Wellness lists. It also received the Platinum Level Bell Seal for Workplace Mental Health for the fourth consecutive year. Brown & Brown, trading at $60.83, is drawing attention for company culture as much as for its role in the insurance sector. The stock has risen 2.9% over...

Aurinia Pharmaceuticals recently highlighted progress in broadening its autoimmune portfolio, advancing aritinercept in clinical development and integrating Kezar Life Sciences’ zetomipzomib program following its acquisition. This move shifts Aurinia’s story from dependence on Lupkynis alone toward a more diversified pipeline that could reshape its long-term autoimmune footprint. We’ll now consider how this broadened autoimmune pipeline, particularly the addition of zetomipzomib, may...

Recent Share Performance and Business Profile Universal Health Services (UHS) has not been tied to a specific fresh headline event, but the stock’s recent performance and business mix across acute care and behavioral health services give investors several data points to assess. The company operates hospitals and behavioral health facilities across the United States, with revenue of about $17.76b and net income of roughly $1.52b, supported by both Acute Care Hospital Services and Behavioral...

Symbotic (SYM) is back in focus after its stock declined more than the broader market, even as Wall Street braces for an earnings report that is expected to show very strong EPS and revenue growth. See our latest analysis for Symbotic. Over the past month, Symbotic’s share price return has fallen 22.89%, contributing to a 37.15% share price decline year to date. However, its 1 year total shareholder return of 9.71% and very large 5 year total shareholder return signal longer term momentum...

If you are wondering whether Merck at US$125.45 still offers value after its strong run, this article explains what the current price may be implying about the stock. Merck's share price performance has been strong recently, with returns of 10.2% over the past 7 days, 4.8% over the past 30 days, 17.8% year to date, 64.5% over 1 year, 21.2% over 3 years and 88.0% over 5 years. Recent coverage of Merck has focused on its position in the pharmaceuticals space and how investors are reacting to...

EnerSys (ENS) has drawn investor attention after launching its EZSelect Lite battery room management system in Switzerland, aiming to automate battery selection and monitoring for industrial users and address inefficiencies in large fleet operations. See our latest analysis for EnerSys. The EZSelect Lite launch lands as EnerSys trades at US$226.34 per share, with a 1 day share price return of 3.38%, a 90 day share price return of 32.08% and a 1 year total shareholder return of 164.17%...

Sunbelt Rentals Holdings (SUNB) just packed several signals into one update, combining record Q4 and full-year revenues with strong free cash flow, fresh 2027 guidance, a higher dividend, and ongoing share repurchases. See our latest analysis for Sunbelt Rentals Holdings. At a share price of $75.18, Sunbelt Rentals Holdings has seen a 15.18% 90 day share price return and a 23.21% 1 year total shareholder return. This suggests that longer term momentum remains intact despite a weaker 7 day...

Carnival (CCL) is back in focus after reporting record quarterly revenue and earnings that topped analyst estimates, even though the stock fell as management paired the results with more cautious forward guidance. See our latest analysis for Carnival. The share price reaction around Carnival’s record quarter has been choppy, with the stock down 7.8% over the past week and 1.6% on the day, yet still showing a 17.6% 90 day share price return and a 67.6% three year total shareholder return that...

Synopsys (SNPS) has just moved its AI driven Multiphysics Fusion platform into customer deployment, tying its electronic design automation tools directly to Ansys analysis at a moment of strong industry focus on advanced chip design. See our latest analysis for Synopsys. Despite the Multiphysics Fusion launch, Synopsys’ recent 1 month share price return is down 13.48%, though the 3 month share price return of 19.59% and 5 year total shareholder return of 63.00% point to stronger long term...

Mixed expectations ahead of Constellation Brands earnings Constellation Brands (STZ) is back in focus as investors look ahead to its upcoming first quarter fiscal 2027 earnings release, with forecasts pointing to modest profit growth but softer expectations after recent EPS estimate revisions. See our latest analysis for Constellation Brands. Constellation Brands shares recently moved up with a 1-day share price return of 1% and a 7-day share price return of 2.32%, although the 1-year total...

Hamilton Lane (HLNE) is in focus after Gridline said it will integrate the firm’s private markets data into AltComply, an AI-based diligence platform used by wealth managers, advisors and compliance teams. See our latest analysis for Hamilton Lane. Despite the Gridline partnership highlighting Hamilton Lane’s role in private markets data, recent momentum has been weak, with the share price down 44.23% year to date and the 1 year total shareholder return declining 46.07%. At the same time, the...

With inflation debates heating up again, Cathie Wood’s latest comments about cooler underlying price pressures and potential support from the Federal Reserve have put growth-oriented technology stocks back in focus. If inflation is closer to 2% than headline data suggests and policy eventually leans more toward supporting growth, companies with strong revenue expansion, solid balance sheets, and moderate volatility could stand out. This article looks at how that backdrop connects to our...

Leggett & Platt (LEG) is back on investors’ radar after its Leggett Dynamics subsidiary launched the Mid-Class Massage System, a non-electronic massage solution now in production with a global automaker and shortlisted for a 2026 industry award. See our latest analysis for Leggett & Platt. That launch comes as Leggett & Platt’s short term momentum has picked up, with a 30 day share price return of 12.62% and a 90 day share price return of 21.09%, while the 1 year total shareholder return of...

Recent interest around MYR Group (MYRG) picked up after Oppenheimer initiated coverage with a Perform rating, highlighting growth opportunities in electrical transmission, data centers, and complex infrastructure, along with stronger free cash flow and insider selling concerns. See our latest analysis for MYR Group. At a share price of $487.33, MYR Group has seen momentum build, with a 3.67% 1 day share price return, 78.20% over 90 days and a 1 year total shareholder return of 170.44%. If you...

AbbVie (NYSE:ABBV) received European Commission approval for Skyrizi to treat children and adolescents with moderate to severe plaque psoriasis. The company also secured approval for Maviret as the only therapy authorized in the EU for both acute and chronic hepatitis C in patients as young as three. These back to back decisions broaden AbbVie’s reach in immunology and virology, particularly in pediatric and earlier stage treatment settings. AbbVie is a large biopharmaceutical company with...

Leadership shifts at JPMorgan have pushed succession planning and risk culture at large US banks into the spotlight. With Jamie Dimon confirming a tighter CEO race and the stock hitting a record high on the news, investors are asking which large-cap US banking stocks could benefit most from this focus on stability and clear governance. This article examines three stocks from a Large-Cap US Banking Stocks screener that appear positively exposed to the JPMorgan leadership story, helping you...

In recent days, Enphase Energy launched its new GaN-based IQ9N microinverter for U.S. residential solar and began U.S. shipments of the IQ9S-3P commercial microinverter, both designed to support high-wattage panels, enhance safety, and integrate with existing Enphase systems under long-term warranties. These product rollouts, combined with Enphase’s expanded focus on data center power and the appointment of a former NVIDIA data center executive to its board, highlight a push to apply its...

Recent Share Performance and Business Profile Federal Signal (FSS) has drawn investor attention after its recent share performance, with the stock last closing at $126.97 and showing gains over the past day, week, month, and past 3 months. The company has a market value of about $7.4b and generates revenue of $2,342.3m with net income of $270.7m. Its operations span two main segments: Environmental Solutions and Safety and Security Systems, serving municipal, governmental, industrial, and...

NuScale Power (SMR) has drawn fresh attention after recent trading left the stock down about 18% over the past month and roughly 74% over the past year, intensifying questions around valuation and risk. See our latest analysis for NuScale Power. At the current share price of $10.07, NuScale Power’s recent moves have been weak, with the 7 day share price return down 14.22% and the year to date share price return down 38.26%, while the 3 year total shareholder return of 47.22% points to a very...

Vertex Pharmaceuticals (VRTX) is back in focus after fresh Phase 3 data for its gene editing therapy CASGEVY in children aged 5 to 11 with severe sickle cell disease and transfusion dependent beta thalassemia. See our latest analysis for Vertex Pharmaceuticals. Recent clinical headlines around CASGEVY and suzetrigine appear to have coincided with stronger interest in Vertex Pharmaceuticals, with a 10.15% 1 month share price return and a 137.47% 5 year total shareholder return suggesting...

Axcelis Technologies Stock Moves After Recent Trading Performance Axcelis Technologies (ACLS) has drawn fresh attention after a single day gain of 7%, adding to a month return of 10% and an advance of 86% over the past 3 months. See our latest analysis for Axcelis Technologies. At a share price of $180.70, Axcelis Technologies has seen strong short term momentum and solid longer term gains, with a 30 day share price return of 10% alongside a 1 year total shareholder return of 154.79%. If...

Walmart expanded the Shapermint shapewear line to 1,600 additional U.S. stores, focusing on size-inclusive and comfort-led apparel. The rollout follows earlier in-store tests and adds to Walmart's broader push into accessible, inclusive fashion. The move increases Walmart's presence in the shapewear category, an area where retailers are competing to meet demand for body-positive, value-focused brands. For investors tracking Walmart, ticker NasdaqGS:WMT, this in-store expansion arrives with...